Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
Clinical trial NCT04426695 · COMPLETED
Trial details
- NCT number
- NCT04426695
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-10
- Primary completion
- 2021-05-07
- Enrollment
- 2252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.